United States securities and exchange commission logo





                          March 25, 2021

       David Zaccardelli, Pharm. D.
       Chief Executive Officer
       Verona Pharma plc
       3 More London Riverside
       London SE1 2RE
       United Kingdom

                                                        Re: Verona Pharma plc
                                                            Registration
Statement on Form S-3
                                                            Filed March 19,
2021
                                                            File No. 333-254530

       Dear Dr. Zaccardelli:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact David
Gessert at 202-551-2326 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences